vir biotechnology inc. - VIR
VIR
Close Chg Chg %
6.00 -0.02 -0.33%
Closed Market
5.98
-0.02 (0.33%)
Volume: 1.11M
Last Updated:
Dec 29, 2025, 4:00 PM EDT
Company Overview: vir biotechnology inc. - VIR
VIR Key Data
| Open $5.92 | Day Range 5.88 - 6.00 |
| 52 Week Range 4.16 - 14.45 | Market Cap $834.75M |
| Shares Outstanding 139.13M | Public Float 94.03M |
| Beta 1.34 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.62 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.01M |
VIR Performance
| 1 Week | 0.00% | ||
| 1 Month | -6.54% | ||
| 3 Months | 4.71% | ||
| 1 Year | -19.62% | ||
| 5 Years | -77.60% |
VIR Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About vir biotechnology inc. - VIR
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
VIR At a Glance
Vir Biotechnology, Inc.
1800 Owens Street
San Francisco, California 94158
| Phone | 1-415-906-4324 | Revenue | 74.21M | |
| Industry | Biotechnology | Net Income | -521,960,000.00 | |
| Sector | Health Technology | Employees | 408 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
VIR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.477 |
| Price to Book Ratio | 0.874 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.203 |
| Enterprise Value to Sales | 1.391 |
| Total Debt to Enterprise Value | 0.948 |
VIR Efficiency
| Revenue/Employee | 181,875.00 |
| Income Per Employee | -1,279,313.725 |
| Receivables Turnover | 14.55 |
| Total Asset Turnover | 0.044 |
VIR Liquidity
| Current Ratio | 8.712 |
| Quick Ratio | 8.712 |
| Cash Ratio | 8.313 |
VIR Profitability
| Gross Margin | 79.241 |
| Operating Margin | -705.372 |
| Pretax Margin | -704.946 |
| Net Margin | -703.403 |
| Return on Assets | -30.852 |
| Return on Equity | -38.091 |
| Return on Total Capital | -41.814 |
| Return on Invested Capital | -35.478 |
VIR Capital Structure
| Total Debt to Total Equity | 8.509 |
| Total Debt to Total Capital | 7.842 |
| Total Debt to Total Assets | 6.876 |
| Long-Term Debt to Equity | 7.836 |
| Long-Term Debt to Total Capital | 7.221 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Vir Biotechnology Inc. - VIR
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.10B | 1.62B | 86.18M | 74.20M | |
Sales Growth
| +1,334.39% | +47.51% | -94.67% | -13.90% | |
Cost of Goods Sold (COGS) incl D&A
| 71.68M | 161.81M | 22.22M | 15.40M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 11.98M | 15.49M | 19.45M | 14.56M | |
Depreciation
| 11.45M | 14.96M | 18.92M | 14.20M | |
Amortization of Intangibles
| 533.00K | 532.00K | 531.00K | 359.00K | |
COGS Growth
| - | +125.75% | -86.27% | -30.66% | |
Gross Income
| 1.02B | 1.45B | 63.96M | 58.80M | |
Gross Income Growth
| - | +42.03% | -95.60% | -8.07% | |
Gross Profit Margin
| +93.46% | +89.99% | +74.22% | +79.24% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 602.99M | 620.92M | 724.97M | 582.22M | |
Research & Development
| 442.19M | 467.87M | 550.92M | 463.19M | |
Other SG&A
| 160.79M | 153.05M | 174.05M | 119.03M | |
SGA Growth
| +65.79% | +2.97% | +16.76% | -19.69% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (138.05M) | 111.14M | 45.19M | 69.27M | |
EBIT after Unusual Expense
| 558.80M | 721.93M | (706.19M) | (592.69M) | |
Non Operating Income/Expense
| (9.00M) | 32.35M | 78.00M | 69.59M | |
Non-Operating Interest Income
| 439.00K | 28.09M | 86.99M | 71.81M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 549.80M | 754.28M | (628.19M) | (523.11M) | |
Pretax Income Growth
| +284.12% | +37.19% | -183.28% | +16.73% | |
Pretax Margin
| +50.19% | +46.68% | -728.93% | -704.95% | |
Income Tax
| 21.22M | 238.44M | (13.08M) | (1.15M) | |
Income Tax - Current - Domestic
| 3.63M | 240.98M | (12.09M) | (289.00K) | |
Income Tax - Current - Foreign
| 2.40M | 12.65M | 75.00K | 2.09M | |
Income Tax - Deferred - Domestic
| 15.19M | (15.19M) | (1.00M) | (3.00M) | |
Income Tax - Deferred - Foreign
| - | - | (59.00K) | 56.00K | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 528.58M | 515.84M | (615.12M) | (521.96M) | |
Minority Interest Expense
| - | - | - | (56.00K) | - |
Net Income
| 528.58M | 515.84M | (615.06M) | (521.96M) | |
Net Income Growth
| +276.98% | -2.41% | -219.24% | +15.14% | |
Net Margin Growth
| +48.25% | +31.92% | -713.69% | -703.40% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 528.58M | 515.84M | (615.06M) | (521.96M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 528.58M | 515.84M | (615.06M) | (521.96M) | |
EPS (Basic)
| 4.0696 | 3.89 | -4.5855 | -3.831 | |
EPS (Basic) Growth
| +262.37% | -4.41% | -217.88% | +16.45% | |
Basic Shares Outstanding
| 129.88M | 132.61M | 134.13M | 136.25M | |
EPS (Diluted)
| 3.9613 | 3.8264 | -4.5855 | -3.831 | |
EPS (Diluted) Growth
| +258.05% | -3.41% | -219.84% | +16.45% | |
Diluted Shares Outstanding
| 133.44M | 134.81M | 134.13M | 136.25M | |
EBITDA
| 432.73M | 848.56M | (641.55M) | (508.86M) | |
EBITDA Growth
| +250.60% | +96.09% | -175.61% | +20.68% | |
EBITDA Margin
| +39.50% | +52.52% | -744.43% | -685.75% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 17.222 | |
| Number of Ratings | 10 | Current Quarters Estimate | -0.539 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -3.385 | |
| Last Quarter’s Earnings | -1.17 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.83 | Next Fiscal Year Estimate | -2.923 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 5 | 10 | 10 |
| Mean Estimate | -0.54 | -0.66 | -3.38 | -2.92 |
| High Estimates | -0.16 | -0.45 | -3.02 | -2.30 |
| Low Estimate | -0.80 | -0.86 | -3.65 | -3.63 |
| Coefficient of Variance | -48.14 | -23.24 | -7.13 | -15.25 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 8 |
| OVERWEIGHT | 2 | 2 | 2 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Vir Biotechnology Inc. - VIR
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Vir Biotechnology Inc. - VIR
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 5, 2025 | Vicki L. Sato Director | 1,210,391 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.64 per share | 6,826,605.24 |
| Apr 7, 2025 | Marianne de Backer Chief Executive Officer; Director | 769,505 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.95 per share | 4,578,554.75 |
| Feb 27, 2025 | Vanina de Verneuil EVP and General Counsel | 79,460 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.14 per share | 726,264.40 |
| Feb 26, 2025 | Jason V. O’Byrne EVP & Chief Financial Officer | 115,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Brent Sabatini SVP, Chief Accounting Officer | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Brent Sabatini SVP, Chief Accounting Officer | 46,627 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.45 per share | 440,625.15 |
| Feb 26, 2025 | Brent Sabatini SVP, Chief Accounting Officer | 48,189 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Vanina de Verneuil EVP and General Counsel | 70,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Vanina de Verneuil EVP and General Counsel | 86,833 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.45 per share | 820,571.85 |
| Feb 26, 2025 | Jason V. O’Byrne EVP & Chief Financial Officer | 80,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Ann M Hanly EVP & Chief Technology Officer | 117,901 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.45 per share | 1,114,164.45 |
| Feb 26, 2025 | Mark D. Eisner EVP and Chief Medical Officer | 80,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Mark D. Eisner EVP and Chief Medical Officer | 115,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Marianne de Backer Chief Executive Officer; Director | 480,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Marianne de Backer Chief Executive Officer; Director | 849,217 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.45 per share | 8,025,100.65 |
| Feb 26, 2025 | George A. Scangos Director | 698,239 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.45 per share | 6,598,358.55 |
| Feb 17, 2025 | Sabatini Brent SVP, Chief Accounting Officer | 28,189 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.15 per share | 257,929.35 |